Headlands Technologies LLC Purchases Shares of 72,335 NewAmsterdam Pharma $NAMSW

Headlands Technologies LLC acquired a new position in NewAmsterdam Pharma (NASDAQ:NAMSW) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 72,335 shares of the company’s stock, valued at approximately $1,546,000.

Separately, Aristeia Capital L.L.C. bought a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at about $397,000.

NewAmsterdam Pharma Trading Down 1.3%

NAMSW opened at $16.30 on Tuesday. The stock has a 50-day moving average of $19.25 and a 200 day moving average of $21.02. NewAmsterdam Pharma has a 12 month low of $12.67 and a 12 month high of $30.45.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical-stage biotechnology company focused on the development of orally delivered peptide therapeutics for the treatment of metabolic diseases. Drawing upon proprietary peptide chemistry and formulation technologies, the company aims to transform injectable treatments for conditions such as type 2 diabetes, obesity and related cardiometabolic disorders into convenient, once-daily oral medications. By harnessing advances in peptide stabilization and targeted delivery, NewAmsterdam Pharma seeks to improve patient adherence and expand access to novel therapies.

The company’s lead program is an oral glucagon‐like peptide‐1 (GLP-1) receptor agonist currently in early clinical trials.